{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:19:38Z","timestamp":1791472778855,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009913","name":"Naval Medical Center San Diego","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009913","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Head and Neck Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Histiocytoses, including Langerhans cell histiocytosis (LCH), comprise a diverse group of histiocytic disorders characterized by the abnormal accumulation and proliferation of histiocytes in various tissues or organs throughout the body, ranging from benign, self-limited conditions to aggressive malignancies and systemic inflammatory syndromes. These lesions present unique diagnostic challenges due to their broad spectrum of clinical presentations, overlapping histopathological and immunophenotypical features, and genetic complexity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review analyzes major histiocytic lesions, focusing on their epidemiology, clinical presentations, histologic and immunophenotypic features, and genetic characteristics to facilitate accurate diagnosis and differentiation among these histiocytoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      LCH, a well-recognized lesion, can affect various organ systems and necessitates differentiation from other types of histiocytoses such as Erdheim-Chester disease (ECD), Rosai-Dorfman-Destombes disease (RDD), and cutaneous and mucocutaneous non-Langerhans cell histiocytoses. Some histiocytic lesions, such as histiocytic sarcoma, are inherently malignant, while others, like hemophagocytic lymphohistiocytosis (HLH), manifest as severe, potentially life-threatening systemic inflammatory syndromes. Recent molecular genetic studies revealed recurrent genetic alterations in the MAPK pathway, such as\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600E and\n                      <jats:italic>MAP2K1<\/jats:italic>\n                      in LCH and ECD, and\n                      <jats:italic>KRAS<\/jats:italic>\n                      ,\n                      <jats:italic>NRAS<\/jats:italic>\n                      , and\n                      <jats:italic>MAP2K1<\/jats:italic>\n                      mutations in a subset of RDD. Malignant histiocytoses frequently show alterations in tumor suppressor genes like\n                      <jats:italic>TP53<\/jats:italic>\n                      and\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Precise classification of histiocytic lesions relies on a comprehensive diagnostic approach that integrates clinical, histologic, immunophenotypic, and genetic data. Recent genetic advances shed light on these conditions\u2019 unique but occasionally overlapping pathogenic mechanisms. Molecular genetics advancements continue to refine diagnostic accuracy and present new therapeutic targets, especially for aggressive or treatment-resistant cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12105-025-01766-2","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T06:19:37Z","timestamp":1740464377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Langerhans Cell Histiocytosis and Other Histiocytic Lesions"],"prefix":"10.1007","volume":"19","author":[{"given":"Reed A.","family":"McKinney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"22","key":"1766_CR1","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","volume":"127","author":"JF Emile","year":"2016","unstructured":"Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127(22):2672\u20132681","journal-title":"Blood"},{"issue":"11","key":"1766_CR2","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML et al (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116(11):1919\u20131923","journal-title":"Blood"},{"key":"1766_CR3","doi-asserted-by":"crossref","unstructured":"Chakraborty R, Abdel-Wahab O, Durham BH (2021) MAP-Kinase-driven hematopoietic neoplasms: a decade of Progress in the Molecular Age. Cold Spring Harb Perspect Med;11(5)","DOI":"10.1101\/cshperspect.a034892"},{"issue":"1","key":"1766_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/pbc.21498","volume":"51","author":"A Guyot-Goubin","year":"2008","unstructured":"Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J (2008) Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000\u20132004. Pediatr Blood Cancer 51(1):71\u201375","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"1766_CR5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/adc.2008.144527","volume":"94","author":"JA Salotti","year":"2009","unstructured":"Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP (2009) Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child 94(5):376\u2013380","journal-title":"Arch Dis Child"},{"issue":"7","key":"1766_CR6","doi-asserted-by":"publisher","first-page":"e1006","DOI":"10.1097\/MPH.0000000000002383","volume":"44","author":"IN Buhtoiarov","year":"2022","unstructured":"Buhtoiarov IN, Mukherjee S, Radivoyevitch T, Incidence (2022) Clinical features, and outcomes of Langerhans Cell Histiocytosis in the United States. J Pediatr Hematol Oncol 44(7):e1006\u2013e15","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"1766_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5114\/pdia.2017.67095","volume":"35","author":"M Jezierska","year":"2018","unstructured":"Jezierska M, Stefanowicz J, Romanowicz G, Kosiak W, Lange M (2018) Langerhans cell histiocytosis in children - a disease with many faces. Recent advances in pathogenesis, diagnostic examinations and treatment. Postepy Dermatol Alergol 35(1):6\u201317","journal-title":"Postepy Dermatol Alergol"},{"issue":"16","key":"1766_CR8","first-page":"1319","volume":"135","author":"C Rodriguez-Galindo","year":"2020","unstructured":"Rodriguez-Galindo C, Allen CE (2020) Langerhans cell Histiocytosis Blood 135(16):1319\u20131331","journal-title":"Langerhans cell Histiocytosis Blood"},{"issue":"5","key":"1766_CR9","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1148\/radiographics.15.5.7501855","volume":"15","author":"JS Meyer","year":"1995","unstructured":"Meyer JS, Harty MP, Mahboubi S, Heyman S, Zimmerman RA, Womer RB et al (1995) Langerhans cell histiocytosis: presentation and evolution of radiologic findings with clinical correlation. Radiographics 15(5):1135\u20131146","journal-title":"Radiographics"},{"issue":"2","key":"1766_CR10","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2214\/AJR.07.3573","volume":"191","author":"N D\u2019Ambrosio","year":"2008","unstructured":"D\u2019Ambrosio N, Soohoo S, Warshall C, Johnson A, Karimi S (2008) Craniofacial and intracranial manifestations of langerhans cell histiocytosis: report of findings in 100 patients. AJR Am J Roentgenol 191(2):589\u2013597","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"1766_CR11","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1002\/1097-0142(19951215)76:12<2471::AID-CNCR2820761211>3.0.CO;2-Z","volume":"76","author":"SE Kilpatrick","year":"1995","unstructured":"Kilpatrick SE, Wenger DE, Gilchrist GS, Shives TC, Wollan PC, Unni KK (1995) Langerhans\u2019 cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer 76(12):2471\u20132484","journal-title":"Cancer"},{"issue":"17","key":"1766_CR12","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1182\/blood.2021014343","volume":"139","author":"G Goyal","year":"2022","unstructured":"Goyal G, Tazi A, Go RS, Rech KL, Picarsic JL, Vassallo R et al (2022) International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood 139(17):2601\u20132621","journal-title":"Blood"},{"key":"1766_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MCP.0000000000000988","volume":"29","author":"FB Jouenne","year":"2023","unstructured":"Jouenne FB, Tazi A (2023) Pulmonary langerhans cell histiocytosis - an update on pathogenesis and treatment. Curr Opin Pulm Med 29:451\u2013458","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"1766_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/bloodadvances.2019000488","volume":"4","author":"KPH Lim","year":"2020","unstructured":"Lim KPH, Milne P, Poidinger M, Duan K, Lin H, McGovern N et al (2020) Circulating CD1c\u2009+\u2009myeloid dendritic cells are potential precursors to LCH lesion CD1a\u2009+\u2009CD207\u2009+\u2009cells. Blood Adv 4(1):87\u201399","journal-title":"Blood Adv"},{"issue":"3","key":"1766_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJM199407213310303","volume":"331","author":"CL Willman","year":"1994","unstructured":"Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH et al (1994) Langerhans\u2019-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med 331(3):154\u2013160","journal-title":"N Engl J Med"},{"issue":"19","key":"1766_CR16","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1182\/blood-2014-05-577825","volume":"124","author":"R Chakraborty","year":"2014","unstructured":"Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H et al (2014) Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124(19):3007\u20133015","journal-title":"Blood"},{"issue":"6","key":"1766_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/gcc.22247","volume":"54","author":"DS Nelson","year":"2015","unstructured":"Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovee JV, Patel B et al (2015) MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 54(6):361\u2013368","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"1766_CR18","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1038\/s41591-019-0653-6","volume":"25","author":"BH Durham","year":"2019","unstructured":"Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S et al (2019) Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med 25(12):1839\u20131842","journal-title":"Nat Med"},{"issue":"1","key":"1766_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nm1694","volume":"14","author":"F Coury","year":"2008","unstructured":"Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C et al (2008) Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 14(1):81\u201387","journal-title":"Nat Med"},{"issue":"10","key":"1766_CR20","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1084\/jem.20030137","volume":"197","author":"NE Annels","year":"2003","unstructured":"Annels NE, Da Costa CE, Prins FA, Willemze A, Hogendoorn PC, Egeler RM (2003) Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med 197(10):1385\u20131390","journal-title":"J Exp Med"},{"key":"1766_CR21","doi-asserted-by":"publisher","first-page":"1275085","DOI":"10.3389\/fimmu.2023.1275085","volume":"14","author":"T Sconocchia","year":"2023","unstructured":"Sconocchia T, Fosselteder J, Sconocchia G, Reinisch A (2023) Langerhans cell histiocytosis: current advances in molecular pathogenesis. Front Immunol 14:1275085","journal-title":"Front Immunol"},{"issue":"2","key":"1766_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/pbc.24367","volume":"60","author":"R Haupt","year":"2013","unstructured":"Haupt R, Minkov M, Astigarraga I, Schafer E, Nanduri V, Jubran R et al (2013) Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer 60(2):175\u2013184","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"1766_CR23","doi-asserted-by":"publisher","first-page":"7254","DOI":"10.1182\/bloodadvances.2023011414","volume":"7","author":"JF Emile","year":"2023","unstructured":"Emile JF, Helias-Rodzewicz Z, Durham BH, Heritier S, da Silva M, Younas K et al (2023) Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type. Blood Adv 7(23):7254\u20137257","journal-title":"Blood Adv"},{"issue":"10295","key":"1766_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(21)00311-1","volume":"398","author":"JF Emile","year":"2021","unstructured":"Emile JF, Cohen-Aubart F, Collin M, Fraitag S, Idbaih A, Abdel-Wahab O et al (2021) Histiocytosis Lancet 398(10295):157\u2013170","journal-title":"Histiocytosis Lancet"},{"issue":"21","key":"1766_CR25","doi-asserted-by":"publisher","first-page":"6568","DOI":"10.1182\/bloodadvances.2023010706","volume":"7","author":"G Goyal","year":"2023","unstructured":"Goyal G, Acosta-Medina AA, Abeykoon JP, Dai C, Ravindran A, Vassallo R et al (2023) Long-term outcomes among adults with Langerhans cell histiocytosis. Blood Adv 7(21):6568\u20136578","journal-title":"Blood Adv"},{"issue":"7","key":"1766_CR26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood-2013-12-543793","volume":"124","author":"B Hervier","year":"2014","unstructured":"Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Neel A et al (2014) Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 124(7):1119\u20131126","journal-title":"Blood"},{"issue":"6","key":"1766_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/bloodadvances.2016001784","volume":"1","author":"JI Estrada-Veras","year":"2017","unstructured":"Estrada-Veras JI, O\u2019Brien KJ, Boyd LC, Dave RH, Durham B, Xi L et al (2017) The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv 1(6):357\u2013366","journal-title":"Blood Adv"},{"issue":"4","key":"1766_CR28","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","volume":"124","author":"EL Diamond","year":"2014","unstructured":"Diamond EL, Dagna L, Hyman DM, Cavalli G, Janku F, Estrada-Veras J et al (2014) Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124(4):483\u2013492","journal-title":"Blood"},{"issue":"13","key":"1766_CR29","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","volume":"120","author":"J Haroche","year":"2012","unstructured":"Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B et al (2012) High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-langerhans cell histiocytoses. Blood 120(13):2700\u20132703","journal-title":"Blood"},{"issue":"2","key":"1766_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2159-8290.CD-15-0913","volume":"6","author":"EL Diamond","year":"2016","unstructured":"Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA et al (2016) Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 6(2):154\u2013165","journal-title":"Cancer Discov"},{"issue":"22","key":"1766_CR31","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/blood.2019003507","volume":"135","author":"G Goyal","year":"2020","unstructured":"Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH et al (2020) Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood 135(22):1929\u20131945","journal-title":"Blood"},{"issue":"4","key":"1766_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/modpathol.2017.160","volume":"31","author":"N Ozkaya","year":"2018","unstructured":"Ozkaya N, Rosenblum MK, Durham BH, Pichardo JD, Abdel-Wahab O, Hameed MR et al (2018) The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol 31(4):581\u2013597","journal-title":"Mod Pathol"},{"issue":"6","key":"1766_CR33","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/jdv.14794","volume":"32","author":"CM Luder","year":"2018","unstructured":"Luder CM, Nordmann TM, Ramelyte E, Muhleisen B, Kerl K, Guenova E et al (2018) Histiocytosis - cutaneous manifestations of hematopoietic neoplasm and non-neoplastic histiocytic proliferations. J Eur Acad Dermatol Venereol 32(6):926\u2013934","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1766_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/his.14569","volume":"80","author":"S Fraitag","year":"2022","unstructured":"Fraitag S, Emile JF (2022) Cutaneous histiocytoses in children. Histopathology 80(1):196\u2013215","journal-title":"Histopathology"},{"issue":"11","key":"1766_CR35","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/jclinpath-2020-206733","volume":"73","author":"C Bruce-Brand","year":"2020","unstructured":"Bruce-Brand C, Schneider JW, Schubert P (2020) Rosai-Dorfman disease: an overview. J Clin Pathol 73(11):697\u2013705","journal-title":"J Clin Pathol"},{"issue":"26","key":"1766_CR36","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1182\/blood-2018-03-839753","volume":"131","author":"O Abla","year":"2018","unstructured":"Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF et al (2018) Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood 131(26):2877\u20132890","journal-title":"Blood"},{"issue":"1","key":"1766_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ajcp\/aqad047","volume":"160","author":"A Ravindran","year":"2023","unstructured":"Ravindran A, Rech KL (2023) How I diagnose Rosai-Dorfman Disease. Am J Clin Pathol 160(1):1\u201310","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"1766_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s44313-024-00022-w","volume":"59","author":"KN Koh","year":"2024","unstructured":"Koh KN, Yoon SH, Kang SH, Kim H, Im HJ (2024) Advancements in the understanding and management of histiocytic neoplasms. Blood Res 59(1):22","journal-title":"Blood Res"},{"key":"1766_CR39","unstructured":"WHO Classification of Tumors Editorial Board Haematolymphoid tumors [Internet]. Lyon (France): International Agency for Research on Cancer; 2024 [cited 2024 OCT 24]. (WHO classification of tumours series, 5th ed.; vol. 11). Available from: https:\/\/tumourclassification.iarc.who.int\/chapters\/63"},{"issue":"5","key":"1766_CR40","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/ajh.27263","volume":"99","author":"GJ Ruan","year":"2024","unstructured":"Ruan GJ, Zanwar S, Ravindran A, Schram S, Abeykoon JP, Hazim A et al (2024) Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis. Am J Hematol 99(5):871\u2013879","journal-title":"Am J Hematol"},{"issue":"7","key":"1766_CR41","doi-asserted-by":"publisher","first-page":"e1263","DOI":"10.1002\/onco.13801","volume":"26","author":"LR Massoth","year":"2021","unstructured":"Massoth LR, Hung YP, Ferry JA, Hasserjian RP, Nardi V, Nielsen GP et al (2021) Histiocytic and dendritic cell sarcomas of hematopoietic origin share Targetable genomic alterations distinct from follicular dendritic cell sarcoma. Oncologist 26(7):e1263\u2013e72","journal-title":"Oncologist"},{"issue":"4","key":"1766_CR42","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3324\/haematol.2019.230375","volume":"105","author":"C Egan","year":"2020","unstructured":"Egan C, Nicolae A, Lack J, Chung HJ, Skarshaug S, Pham TA et al (2020) Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups. Haematologica 105(4):951\u2013960","journal-title":"Haematologica"},{"issue":"1","key":"1766_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ejh.12755","volume":"97","author":"J Ansari","year":"2016","unstructured":"Ansari J, Naqash AR, Munker R, El-Osta H, Master S, Cotelingam JD et al (2016) Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. Eur J Haematol 97(1):9\u201316","journal-title":"Eur J Haematol"},{"issue":"10","key":"1766_CR44","doi-asserted-by":"publisher","first-page":"100268","DOI":"10.1016\/j.modpat.2023.100268","volume":"36","author":"A Ravindran","year":"2023","unstructured":"Ravindran A, Dasari S, Ruan GJ, Artymiuk CJ, He R, Viswanatha DS et al (2023) Malignant histiocytosis comprises a phenotypic spectrum that parallels the lineage differentiation of monocytes, macrophages, dendritic cells, and Langerhans Cells. Mod Pathol 36(10):100268","journal-title":"Mod Pathol"},{"issue":"3","key":"1766_CR45","doi-asserted-by":"publisher","first-page":"136","DOI":"10.3892\/mco.2022.2569","volume":"17","author":"O Imataki","year":"2022","unstructured":"Imataki O, Uemura M, Fujita H, Kadowaki N (2022) Application of PD-L1 blockade in refractory histiocytic sarcoma: a case report. Mol Clin Oncol 17(3):136","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"1766_CR46","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.berh.2020.101515","volume":"34","author":"G Griffin","year":"2020","unstructured":"Griffin G, Shenoi S, Hughes GC (2020) Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol 34(4):101515","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"1766_CR47","doi-asserted-by":"publisher","first-page":"507","DOI":"10.5858\/arpa.2020-0802-RA","volume":"146","author":"TS Ponnatt","year":"2022","unstructured":"Ponnatt TS, Lilley CM, Mirza KM (2022) Hemophagocytic Lymphohistiocytosis. Arch Pathol Lab Med 146(4):507\u2013519","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"1766_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S et al (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124\u2013131","journal-title":"Pediatr Blood Cancer"},{"key":"1766_CR49","doi-asserted-by":"publisher","first-page":"102143","DOI":"10.1016\/j.eclinm.2023.102143","volume":"62","author":"A Abdelhay","year":"2023","unstructured":"Abdelhay A, Mahmoud AA, Al Ali O, Hashem A, Orakzai A, Jamshed S (2023) Epidemiology, characteristics, and outcomes of adult haemophagocytic lymphohistiocytosis in the USA, 2006-19: a national, retrospective cohort study. EClinicalMedicine 62:102143","journal-title":"EClinicalMedicine"},{"issue":"23","key":"1766_CR50","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Rosee","year":"2019","unstructured":"La Rosee P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N et al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23):2465\u20132477","journal-title":"Blood"},{"issue":"21","key":"1766_CR51","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1182\/blood.2019002289","volume":"134","author":"M Vallurupalli","year":"2019","unstructured":"Vallurupalli M, Berliner N (2019) Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis. Blood 134(21):1783\u20131786","journal-title":"Blood"},{"issue":"7","key":"1766_CR52","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia 36(7):1703\u20131719","journal-title":"Leukemia"},{"issue":"7","key":"1766_CR53","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2008-03-147017","volume":"112","author":"JK Chan","year":"2008","unstructured":"Chan JK, Lamant L, Algar E, Delsol G, Tsang WY, Lee KC et al (2008) ALK\u2009+\u2009histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood 112(7):2965\u20132968","journal-title":"Blood"},{"issue":"5","key":"1766_CR54","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41379-018-0168-6","volume":"32","author":"KTE Chang","year":"2019","unstructured":"Chang KTE, Tay AZE, Kuick CH, Chen H, Algar E, Taubenheim N et al (2019) ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol 32(5):598\u2013608","journal-title":"Mod Pathol"},{"issue":"2","key":"1766_CR55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood.2021013338","volume":"139","author":"PG Kemps","year":"2022","unstructured":"Kemps PG, Picarsic J, Durham BH, Helias-Rodzewicz Z, Hiemcke-Jiwa L, van den Bos C et al (2022) ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood 139(2):256\u2013280","journal-title":"Blood"}],"container-title":["Head and Neck Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-025-01766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12105-025-01766-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12105-025-01766-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:01:50Z","timestamp":1767592910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12105-025-01766-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1766"],"URL":"https:\/\/doi.org\/10.1007\/s12105-025-01766-2","relation":{},"ISSN":["1936-0568"],"issn-type":[{"value":"1936-0568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"17 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"For this type of study informed consent was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study consent for publication was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"26"}}